XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.4.0.3

Segment Information (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Jan. 31, 2016 | Apr. 30, 2015
Segment Reporting [Abstract] |  |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
Three Months Ended January 31, 2016 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 416 |  |  | $ | 2,136 |  |  | $ | — |  |  | $ | 2,552 |
Direct cost of services |  |  | (479 | ) |  |  | (1,624 | ) |  |  | — |  |  |  | (2,103 | )
Sales and marketing costs |  |  | (183 | ) |  |  | (569 | ) |  |  | — |  |  |  | (752 | )
Other operating expenses |  |  | — |  |  |  | (950 | ) |  |  | (553 | ) |  |  | (1,503 | )
Stock-based compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (567 | ) |  |  | (567 | )
Segment profit (loss) |  | $ | (246 | ) |  | $ | (1,007 | ) |  | $ | (1,120 | ) |  | $ | (2,373 | )
Three Months Ended January 31, 2015 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 453 |  |  | $ | 1,376 |  |  | $ | — |  |  | $ | 1,829 |
Direct cost of services |  |  | (672 | ) |  |  | (1,300 | ) |  |  | — |  |  |  | (1,972 | )
Sales and marketing costs |  |  | (366 | ) |  |  | (613 | ) |  |  | — |  |  |  | (979 | )
Other operating expenses |  |  | — |  |  |  | (1,028 | ) |  |  | (612 | ) |  |  | (1,640 | )
Stock-based compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (657 | ) |  |  | (657 | )
Segment profit (loss) |  | $ | (585 | ) |  | $ | (1,565 | ) |  | $ | (1,269 | ) |  | $ | (3,419 | )
Nine Months Ended January 31, 2016 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 1,387 |  |  | $ | 6,958 |  |  | $ | — |  |  | $ | 8,345 |
Direct cost of services |  |  | (1,634 | ) |  |  | (4,654 | ) |  |  | — |  |  |  | (6,288 | )
Sales and marketing costs |  |  | (716 | ) |  |  | (1,800 | ) |  |  | — |  |  |  | (2,516 | )
Other operating expenses |  |  | — |  |  |  | (2,755 | ) |  |  | (2,463 | ) |  |  | (5,218 | )
Stock-based compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (2,090 | ) |  |  | (2,090 | )
Segment profit (loss) |  | $ | (963 | ) |  | $ | (2,251 | ) |  | $ | (4,553 | ) |  | $ | (7,767 | )
Nine Months Ended January 31, 2015 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 1,245 |  |  | $ | 4,377 |  |  | $ | — |  |  | $ | 5,622 |
Direct cost of services |  |  | (2,171 | ) |  |  | (3,205 | ) |  |  | — |  |  |  | (5,376 | )
Sales and marketing costs |  |  | (1,243 | ) |  |  | (1,650 | ) |  |  | — |  |  |  | (2,893 | )
Other operating expenses |  |  | — |  |  |  | (3,490 | ) |  |  | (2,413 | ) |  |  | (5,903 | )
Stock-based compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (2,284 | ) |  |  | (2,284 | )
Segment profit (loss) |  | $ | (2,169 | ) |  | $ | (3,968 | ) |  | $ | (4,697 | ) |  | $ | (10,834 | )
| (1) | Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
| The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
Year Ended April 30, 2015 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 1,663 |  |  | $ | 7,200 |  |  | $ | — |  |  | $ | 8,863 |
Direct cost of services |  |  | (2,711 | ) |  |  | (4,877 | ) |  |  | — |  |  |  | (7,588 | )
Sales and marketing costs |  |  | (1,514 | ) |  |  | (2,208 | ) |  |  | — |  |  |  | (3,722 | )
Other operating expenses |  |  | — |  |  |  | (4,493 | ) |  |  | (3,136 | ) |  |  | (7,729 | )
Stock compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (3,162 | ) |  |  | (3,162 | )
Segment profit (loss) |  | $ | (2,562 | ) |  | $ | (4,378 | ) |  | $ | (6,298 | ) |  | $ | (13,238 | )
Year Ended April 30, 2014 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 2,264 |  |  | $ | 9,286 |  |  | $ | — |  |  | $ | 11,550 |
Direct cost of services |  |  | (2,667 | ) |  |  | (3,496 | ) |  |  | — |  |  |  | (6,163 | )
Sales and marketing costs |  |  | (1,723 | ) |  |  | (1,080 | ) |  |  | — |  |  |  | (2,803 | )
Other operating expenses |  |  | — |  |  |  | (2,209 | ) |  |  | (3,828 | ) |  |  | (6,037 | )
Stock compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (2,807 | ) |  |  | (2,807 | )
Segment loss |  | $ | (2,126 | ) |  | $ | 2,501 |  |  | $ | (6,635 | ) |  | $ | (6,260 | )
| (1) | Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration